Author(s): Kala M, Miravalle A, Vollmer T
Abstract Share this page
Abstract Glatiramer acetate (GA, Copaxone®, co-polymer 1) is an immunomodulatory therapy approved in 1996 by the United States Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis. GA has a good safety profile, moderate efficacy, and a unique mode of action. Recent evidence in an animal model of MS, experimental autoimmune encephalomyelitis (EAE), suggests that GA effects on NK cells and B cells may contribute to therapeutic efficacy. We review the mechanism of action of GA, with particular focus on recent data suggesting a role for regulatory B cells. Copyright © 2011 Elsevier B.V. All rights reserved.
This article was published in J Neuroimmunol
and referenced in Journal of Multiple Sclerosis